"Įduardo Molinari, Senior Director of The New Market Development Team in Latin America, BeiGene, said: "Following the recent launch of Baiyueze ® in Brazil, Chile and Ecuador, three more indications were approved in Uruguay. Now, with the approval of Baiyueze ®, we are able to bring a completely new treatment plan to MCL, MZL and WM patients in Uruguay, which will give them new hope and improve their treatment outcomes. The design of Baiyueze ® aims to maximize the share of BTK targets and minimize off-target effects, thereby optimizing the treatment experience of patients.
BeiGene and Adium have signed an exclusive distribution agreement, and Adium will be responsible for the commercialization of Baiyueze ® in Latin America.ĭr Karina Cicinelli, Medical Director at Adium, said: "For patients with B-cell malignancies, the tolerance of treatment is an important consideration in the selection of BTK inhibitors. The company today announced that ® Zebutinib has been approved in Uruguay for the treatment of adult patients with previously treated sleeve cell lymphoma (MCL), recurrent or refractory borderline lymphoma (MZL), and fahrenheit macroglobulinemia (WM).
Following previous approvals in Brazil, Chile and Ecuador, Paragon is ® now approved in four countries in Latin Americaīased on an exclusive distribution agreement, Adium will be responsible for the commercialization of Joyson ® in Latin AmericaīEIJING, China, CAMBRIDGE, MASSACHUSETTS, USA, and MONTEVIDEO, URUGUAY AP/PRNEWS/ - BeiGene (NASDAQ: BGNE HKEx: 06160 SSE: 688235) is a global science-based biotechnology company focused on developing innovative, affordable medicines designed to improve treatment outcomes and access for patients around the world.
0 kommentar(er)
